An exploration of the conflicts raised by building an academic cancer
research center with the money and active participation of a
petrochemical billionaire.
As caviar-topped sweet potato cubes and gulab jamon skewers circulated,
with gold-encrusted living statues posing in the corner, the
Massachusetts Institute of Technology community feted last Friday the
generous philanthropy of David H. Koch, whose $100 million gift helped
build the new cancer research institute that bears his name.
The richest man in New York City stood tall above the crowd, as his wife
Julia, brother Charles, and other members of the Koch family shared the
glorious moment, captured by fast-snapping photographers. His
bodyguards, thick-necked and glowering in ill-fitting suits that bore a
small gold Koch Industries pin on the lapel, stood by as cancer
researchers, MIT officials, and biotechnology
executives enjoyed the open bar and discussed the future of the battle
against cancer. The lab technicians who have already been working for
weeks in the building were easy to identify by their scruffy haircuts,
informal wear, and relative youth, faintly bemused by the mostly
middle-aged hobnobbers.
Koch’s name was emblazoned on the nametags worn by the scientists and
practically every surface of the new building with a logo that strongly
resembles that of his petrochemical conglomerate.
This reception took place in the lobby of the David H. Koch Integrative
Cancer Institute after the formal dedication of the building in a party
tent wedged in back, where Koch was effusively thanked by politicians
and scientists for his generosity and commitment to tackling the disease
that kills one in four Americans, about 560,000 a year. Koch Institute
scientists described the innovative technologies and research they are
bringing to bear to treat cancer, from nanoparticles to deep sequencing.
They discussed new breakthroughs in understanding the unique genetic
nature of the various diseases that cause cancers to spread in the human
body, promising new pathways of treatment for patients.
Strangely, however, during the entire two-hour program, not a single
participant mentioned environmental carcinogens or any other external
factors in causing cancer. Dr. Alice T. Shaw, a practicing oncologist at
Massachusetts General Hospital, professor at Harvard Medical School, and
clinical investigator at the Koch Institute gave an extended discussion
of her specialty, lung cancer, about underlying genetic abnormalities,
targeted mutations, and smart drugs. Not once did she mention the
overwhelming role of cigarette smoking in making the once-rare disease
one of the top killers in the world.
Dr. Tyler Jacks, the David H. Koch Professor of Biology and director of
the institute, Dr. Jacqueline Lees, the institute’s associate director,
and institute professors Dr. Phillip Sharp and Dr. Robert Langer also
failed to address environmental causes of cancer during their allotted
moments in the program. A lavishly produced video, which tied the launch
of the Koch Institute to the celebration of
MIT’s sesquicentennial, showed graduate
students sitting in a classroom beneath a portrait of David Koch. The
film exclusively discussed work to treat cancer, but not the causes.
Why this unusual omission?